Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net sales	$ 3,389	$ 3,026
Cost of products sold	1,040	955
Gross profit	2,349	2,071
Operating expenses:
Selling, general and administrative expenses	1,215	1,060
Research and development expenses	337	319
Royalty expense	11	12
Amortization expense	203	198
Contingent consideration net expense (benefit)	12	12
Restructuring net charges (credits)	20	4
Operating expenses	1,797	1,605
Operating income (loss)	552	466
Other income (expense):
Interest expense	(65)	(279)
Other, net	(43)	(31)
Income (loss) before income taxes	444	156
Income tax expense (benefit)	131	45
Net income (loss)	314	110
Preferred stock dividends	(14)	(14)
Net income (loss) attributable to noncontrolling interests	0	0
Net income (loss) attributable to Boston Scientific common stockholders	$ 300	$ 97
Net income (loss) per common share — basic	$ 0.21	$ 0.07
Net income (loss) per common share — diluted	$ 0.21	$ 0.07
Weighted-average shares outstanding
Basic	1,435.8	1,427.8
Diluted	1,446.0	1,438.4